NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

NWBO 2024 10K

https://www.otcmarkets.com/filing/html?id=18330703&guid=66b-kWEDbPruQOh#NWBO-20241231X10K_HTM_ITEM7

As previously reported, we have been developing a manufacturing facility in Sawston, U.K. The Sawston facility contains a total of 88,345 square feet on two floors. The initial production capacity comprises two manufacturing suites, occupying approximately 4,400 square feet on the ground floor. These two suites, together with some additional support and storage space, have anticipated potential capacity to produce dendritic cell vaccines for about 40 to 45 patients per month, or approximately 450 to 500 patients annually. The buildout of Phases 1A and 1B of the facility have been completed. We also continue to conduct activities in the GMP (clean room) facility in London.

So we're looking at ~1000 patients a year initially with the buildout of a grade C Lab.